IL1B and diabetes mellitus: Among other prognostic studies, a much larger retrospective study showed that high‐risk patients (as identified by a combination of smoking, diabetes and IL1 genotypes) benefitted more from two recall visits per year compared with low‐risk patients (Giannobile et al. 2013).